The "Vestibular Schwannoma – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about 10+ companies and 10+ ...

A new study at Massachusetts Eye and Ear showed that in some cases of vestibular schwannoma, a sometimes-lethal tumor often associated with neurofibromatosis 2 (NF2), secretions from the tumor contain ...

Removing a vestibular schwannoma - a slow-growing, benign tumor that develops in the nerves connecting the inner ear to the brain - is a delicate procedure. Surgeons must differentiate the tumor from ...

Radiotherapy was effective in controlling growing vestibular schwannomas over 10 years, regardless of pretreatment tumor size or location. Compared with previous, small studies, these results offer “a ...

Salicylates, a class of non-steroidal inflammatory drugs (NSAIDs), reduced the proliferation and viability of cultured vestibular schwannoma cells that cause a sometimes lethal intracranial tumor that ...

Neurofibromatosis type 2 (NF2) is an autosomal‐dominant disorder characterised by the development of multiple tumours, most notably bilateral vestibular schwannomas. These benign tumours originate ...

Unilateral vestibular schwannomas affect only one ear. They account for approximately 8 percent of all tumors inside the skull; one out of every 100,000 individuals per year develops a vestibular ...

A new understanding of the pathobiology behind a head and neck tumor has been uncovered that may someday lead to new methods of targeted drug therapy, scientists report. Researchers from the ...

image: Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology's Program in Speech and Hearing Bioscience and Technology have demonstrated that ...

Losartan, a popular medication used to treat hypertension, could improve hearing in patients who developed hearing loss due to vestibular schwannoma (VS). Researchers from the Massachusetts General ...

Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs).